TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04929223: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Sponsor: Hoffmann-La Roche · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 542 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT04929223 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04929223 Rescue Dossier →